Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Winter is coming: managing COPD exacerbations in the current environment
Dr Emmet O’Brien, Consultant Respiratory Physician Beaumont Hospital, Dublin
Webinar | 23rd September | 01:00 PM GMT
PM-IE-CPU-WCNT-200007
Winter is coming: managing COPD exacerbations in the current environment
Dr Emmet O’Brien, Consultant Respiratory Physician Beaumont Hospital, Dublin
Webinar | 23rd September | 01:00 PM GMT
PM-IE-CPU-WCNT-200007
Relvar Ellipta
25% more patients improve asthma control vs. other ICS/LABAs in everyday clinical practice. 1
More Information
Dovato (dolutegravir and lamivudine)
An innovative treatment for your patients living with HIV-1. Dovato is a complete two-drug regimen, offering convenient dosing, available in a once daily pill.
Explore Bexsero - Meningococcal Group B Vaccine
Bexsero is indicated for the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease(IMD) caused by Neisseria meningitidis group B.
Using dual therapy or triple therapy for your patients?
The IMPACT trial was the first trial to assess the efficacy and safety of single inhaler Triple Therapy TRELEGY▼ Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and a LAMA/LABA (UMEC/VI). 2
Abbreviations
FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Trade marks are owned by or licensed to the GSK group of companies.
